|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00001062 |
To determine whether alternating oral ganciclovir with intravenous ( IV ) ganciclovir can prevent relapse of Cytomegalovirus ( CMV ) retinitis and improve quality of life in AIDS patients.
A systemic treatment strategy for CMV retinitis is needed that will be effective yet convenient to administer, without the need for a permanent indwelling IV catheter. Although oral ganciclovir has been used as maintenance following induction with IV ganciclovir, patients with reactivation of disease must be reinduced IV. A fixed-schedule regimen in which oral and IV ganciclovir are alternated may prevent reactivation and progression of disease, as opposed to the current therapeutic strategy in which changes in therapy are event-driven. Also, the duration of intermittent IV therapy required to control disease may be short enough to eliminate the need for an indwelling catheter.
Condition | Intervention | Phase |
Cytomegalovirus Retinitis HIV Infections |
Drug: Ganciclovir |
Phase I |
MedlinePlus related topics: | AIDS Cytomegalovirus Infections |
Drug Information available for: | Ganciclovir Ganciclovir sodium |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase I Study of a Fixed-Schedule Regimen of Alternating Oral and Intravenous Ganciclovir for Treatment of Cytomegalovirus Retinitis |
Estimated Enrollment: | 25 |
A systemic treatment strategy for CMV retinitis is needed that will be effective yet convenient to administer, without the need for a permanent indwelling IV catheter. Although oral ganciclovir has been used as maintenance following induction with IV ganciclovir, patients with reactivation of disease must be reinduced IV. A fixed-schedule regimen in which oral and IV ganciclovir are alternated may prevent reactivation and progression of disease, as opposed to the current therapeutic strategy in which changes in therapy are event-driven. Also, the duration of intermittent IV therapy required to control disease may be short enough to eliminate the need for an indwelling catheter.
Patients receive IV induction with ganciclovir for 2 weeks followed by an alternating course of 3 weeks of oral ganciclovir and 1 week of IV drug for four cycles (16 weeks). If CMV retinitis fails to arrest after initial induction, IV ganciclovir is administered for an additional 2 weeks.
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Prior Medication:
Excluded:
United States, California | |||||
UCLA CARE Ctr | |||||
Los Angeles, California, United States, 90095 | |||||
United States, Illinois | |||||
Lakeside Veterans Adm / Northwestern Univ Med School | |||||
Chicago, Illinois, United States, 60611 | |||||
Illinois Masonic Med Ctr | |||||
Chicago, Illinois, United States, 606575147 | |||||
Louis A Weiss Memorial Hosp | |||||
Chicago, Illinois, United States, 60640 | |||||
United States, Maryland | |||||
Johns Hopkins Hosp | |||||
Baltimore, Maryland, United States, 21287 | |||||
United States, New York | |||||
Cornell Univ Med Ctr | |||||
New York, New York, United States, 10021 | |||||
Saint Clare's Hosp and Health Ctr | |||||
New York, New York, United States, 10019 | |||||
United States, North Carolina | |||||
Univ of North Carolina | |||||
Chapel Hill, North Carolina, United States, 275997215 | |||||
United States, Washington | |||||
Univ of Washington | |||||
Seattle, Washington, United States, 981224304 |
Study Chair: | Holland GN | |
Study Chair: | Hardy WD |
Click here for more information about Ganciclovir 
  |
Study ID Numbers: | ACTG 278 |
First Received: | November 2, 1999 |
Last Updated: | August 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00001062 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|